JJ Vredenburgh, A Desjardins, JE Herndon… - Journal of clinical …, 2007 - ascopubs.org
Purpose The prognosis for patients with recurrent glioblastoma multiforme is poor, with a
median survival of 3 to 6 months. We performed a phase II trial of bevacizumab, a …